Early mortality after implantable cardioverter defibrillator: Incidence and associated factors.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 02 2020
Historique:
received: 13 06 2019
revised: 09 09 2019
accepted: 16 09 2019
pubmed: 23 11 2019
medline: 15 12 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

According to guidelines, implantable cardioverter defibrillator (ICD) candidates must have a "reasonable expectation of survival with a good functional status >1 year". Identifying risk for early mortality in ICD candidates could be challenging. We aimed to identify factors associated with a ≤1-year survival among patients implanted with ICDs. The DAI-PP program was a multicenter, observational French study that included all patients who received a primary prevention ICD in the 2002-2012 period. Characteristics of patients who survived ≤1 year following the implantation were compared with those who survived >1 year, and predictors of early death determined. Out of the 5539 enrolled patients, survival status at 1 year was known for a total of 5,457, and overall 230 (4.2%) survived ≤1 year. Causes of death were similar in the two groups. Patients with ≤1-year survival had lower rates of appropriate (14 vs. 23%; P = 0.004) and inappropriate ICD therapies (2 vs. 7%; P = 0.009) than patients who lived >1 year after ICD implantation. In multivariate analysis, older age, higher NYHA class (≥III), and atrial fibrillation were significantly associated with ≤1-year survival. Presence of all 3 risk factors was associated with a cumulative 22.63% risk of death within 1 year after implantation. This is the largest study determining the factors predicting early mortality after ICD implantation. Patients dying within the first year had low ICD therapy rates. A combination of clinical factors could potentially identify patients at risk for early mortality to help improve selection of ICD candidates.

Sections du résumé

BACKGROUND
According to guidelines, implantable cardioverter defibrillator (ICD) candidates must have a "reasonable expectation of survival with a good functional status >1 year". Identifying risk for early mortality in ICD candidates could be challenging. We aimed to identify factors associated with a ≤1-year survival among patients implanted with ICDs.
METHODS
The DAI-PP program was a multicenter, observational French study that included all patients who received a primary prevention ICD in the 2002-2012 period. Characteristics of patients who survived ≤1 year following the implantation were compared with those who survived >1 year, and predictors of early death determined.
RESULTS
Out of the 5539 enrolled patients, survival status at 1 year was known for a total of 5,457, and overall 230 (4.2%) survived ≤1 year. Causes of death were similar in the two groups. Patients with ≤1-year survival had lower rates of appropriate (14 vs. 23%; P = 0.004) and inappropriate ICD therapies (2 vs. 7%; P = 0.009) than patients who lived >1 year after ICD implantation. In multivariate analysis, older age, higher NYHA class (≥III), and atrial fibrillation were significantly associated with ≤1-year survival. Presence of all 3 risk factors was associated with a cumulative 22.63% risk of death within 1 year after implantation.
CONCLUSIONS
This is the largest study determining the factors predicting early mortality after ICD implantation. Patients dying within the first year had low ICD therapy rates. A combination of clinical factors could potentially identify patients at risk for early mortality to help improve selection of ICD candidates.

Identifiants

pubmed: 31753583
pii: S0167-5273(19)33062-1
doi: 10.1016/j.ijcard.2019.09.033
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-118

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Rodrigue Garcia (R)

CHU Poitiers, 86021, Poitiers, France.

Serge Boveda (S)

Clinique Pasteur, 31076, Toulouse, France.

Pascal Defaye (P)

CHU Michallon, 38700, Grenoble, France.

Nicolas Sadoul (N)

CHU Brabois, 54500, Vandœuvre-lès-Nancy, France.

Kumar Narayanan (K)

Maxcure Hospitals, Hyderabad, 500081, Telangana, India; Paris Cardiovascular Research Center (Inserm U970), 75015, Paris, France.

Marie-Cécile Perier (MC)

Paris Cardiovascular Research Center (Inserm U970), 75015, Paris, France.

Didier Klug (D)

CHRU Lille, 59000, Lille, France.

Laurent Fauchier (L)

CHU Trousseau, 37170, Chambray-les-Tours, France.

Christophe Leclercq (C)

CHU Pontchaillou, 35000, Rennes, France.

Dominique Babuty (D)

CHU Trousseau, 37170, Chambray-les-Tours, France.

Pierre Bordachar (P)

CHU Haut-Lévêque, 33604, Pessac, France.

Daniel Gras (D)

Hôpital Privé Du Confluent, 44277, Nantes, France.

Jean-Claude Deharo (JC)

CHU La Timone, 13005, Marseille, France.

Olivier Piot (O)

Centre Cardiologique Du Nord, 93200, Saint Denis, France.

Rui Providencia (R)

Clinique Pasteur, 31076, Toulouse, France; Barts Heart Centre, Barts Health NHS Trust, EC1A 7BE, London, UK.

Eloi Marijon (E)

Paris Cardiovascular Research Center (Inserm U970), 75015, Paris, France; Clinique Pasteur, 31076, Toulouse, France; Barts Heart Centre, Barts Health NHS Trust, EC1A 7BE, London, UK; AP-HP, Hôpital Européen Georges Pompidou, 75015 Paris and Université Paris Descartes, 75006, Paris, France.

Vincent Algalarrondo (V)

AP-HP, CHU Bichat Claude Bernard and Université Paris Diderot, 75018, Paris, France. Electronic address: vincent.algalarrondo@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH